Clinical Scorecard: Frequency and Associated Risk Factors of Asymptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Approximately 27% of AF patients are asymptomatic with large variability based on risk factor prevalence
• Male sex, diabetes mellitus, chronic kidney disease, and stroke/TIA are positively associated with asymptomatic AF
• Heart failure, catheter ablation, beta-blockers, and antiarrhythmics are negatively associated with asymptomatic AF

Guideline-Based Recommendations

Diagnosis

• European Society of Cardiology (ESC) recommends heart rhythm assessment for individuals ≥65 years at each healthcare encounter
• More thorough screening recommended for individuals ≥75 years or ≥65 years with additional CHA2DS2-VA risk factors using non-invasive ECG modalities
• No specific AF screening recommendations from USPSTF and ACC/AHA due to insufficient evidence

Management

• Early identification and management of asymptomatic AF is crucial to improve outcomes and attenuate disease progression
• Consider rhythm and rate control interventions tailored to symptomatic status and risk factors

Monitoring & Follow-up

• Regular assessment of symptom status using tools like the European Heart Rhythm Association (EHRA) score
• Monitor for disease progression and adverse clinical outcomes regardless of symptom presence

Risks

• Asymptomatic AF patients have similar risks of stroke and mortality as symptomatic patients
• Higher risk of disease progression in asymptomatic individuals necessitates vigilant screening and management

Patient & Prescribing Data

Patients with atrial fibrillation, including asymptomatic and symptomatic subgroups

Use of catheter ablation, beta-blockers, and antiarrhythmics is associated with lower likelihood of asymptomatic status; treatment decisions should consider symptom presence and risk factors

Clinical Best Practices

• Incorporate risk factor assessment (male sex, diabetes, CKD, stroke/TIA) to identify patients at higher risk for asymptomatic AF
• Use validated symptom assessment tools such as the EHRA score to differentiate symptomatic from asymptomatic patients
• Implement routine ECG-based screening in older adults and those with risk factors to detect asymptomatic AF early
• Tailor management strategies to individual patient profiles considering symptom status and comorbidities
• Educate patients on the importance of AF detection even in absence of symptoms to prevent adverse outcomes

References

• European Society of Cardiology Guidelines on Atrial Fibrillation
• American College of Cardiology/American Heart Association AF Guidelines
• USPSTF Recommendations on AF Screening
• European Heart Rhythm Association Symptom Classification (EHRA Score)
• PROSPERO Registration CRD42024578738